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FoundationSerum cardiac troponin I and T (cTnT) are sensitive and
speciﬁc biomarkers for myocardial damage, and their mea-
surement is recommended for accurate diagnosis of acute
myocardial infarction (1). Elevated levels of serum cardiac
troponin measured by conventional cardiac troponin assay
correlate with adverse outcome in patients with both acutecular Medicine, Graduate School of Medical
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, 2012; revised manuscript received March 4,and chronic heart failure (HF) (2–4). However, in the
majority of patients with HF, serum cardiac troponin levels
are lower than the assay detection limits. Recently, a novel
and highly sensitive cTnT (hs-TnT) assay has made it
possible to detect low-grade circulating cTnT levels below the
detection levels of conventional assays. This assay improvesSee page 641the diagnostic accuracy for myocardial infarction (5); prog-
nostic discrimination, compared with conventional assays in
patients with HF (6); and risk stratiﬁcation for cardiovascular
events and mortality in both patients with stable coronary
artery disease (CAD) (7) and the general population (8–10).
Abbreviations
and Acronyms
Ao = aortic root
CAD = coronary artery
disease
CFR = coronary ﬂow reserve
CI = conﬁdence interval
CMVD = coronary
microvascular dysfunction
CS = coronary sinus
cTnT = cardiac troponin T
FV = femoral vain
IL = interleukin
hs-CRP = high-sensitivity
C-reactive protein
hs-TnT = highly-sensitive
troponin T
LVEDP = left ventricular
end-diastolic pressure
OR = odds ratio
TNF = tumor necrosis factor
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633The levels of circulating cardiac troponin are modestly and
persistently elevated in patients with stable HF, regardless of
overt CAD (11). Various reasons have been proposed for the
high serum troponin levels in patients with HF, including
increased wall stress, myocyte damage from inﬂammatory
cytokines or oxidative stress (11), altered calcium handling
(12), and coronary microvascular dysfunction (CMVD)
(13). At the molecular level, cardiac troponin is released from
cardiomyocytes in response to myocardial necrosis, apoptosis,
troponin degradation, increased membrane permeability, and
stimulation of stretch-responsive integrins (11,14). Therefore,
it is rational to speculate that persistent troponinemia may
represent ongoing subclinical myocardial damage. However,
this concept has not been demonstrated clinically, because
serum cardiac troponin levels are affected by various clinical
factors such as renal dysfunction (6,15), CAD (7,11), and
skeletal muscle disease (16). In this study of patients with HF,
we directly measured transcardiac cTnT release from non-
ischemic failing myocardium by hs-TnT assay to identify the
factors associated with cTnT release, with a special focus on
wall stress, inﬂammatory cytokines, oxidative stress, and
CMVD.Methods
Patient population. We evaluated 90 consecutive patients
with nonischemic HF who underwent cardiac catheteriza-
tion for evaluation of hemodynamics and coronary artery
between January 2007 and May 2012 at Kumamoto Uni-
versity Hospital. Eligible patients were 20 years or older with
HF consistent with the American College of Cardiology/
American Heart Association Stage B or C classiﬁcation
(17). All patients were clinically stable and under optimal
medical therapy for HF (18), including stable doses of an
angiotensin-converting enzyme inhibitor or angiotensin II
receptor blocker, a beta-blocker, and an aldosterone blocker
if not contraindicated. The control group comprised 47 non-
HF patients who also underwent cardiac catheterization for
suspected angina pectoris and were conﬁrmed as normal by
coronary angiography, which also showed no wall motion
abnormality, cardiac hypertrophy, or valvular heart disease.
The following exclusion criteria were applied during patient
selection: decompensated HF, ischemic HF, acute coronary
syndrome, signiﬁcant coronary artery stenosis (>50%),
myocarditis, muscular dystrophy, polymyositis, implanted
cardiac resynchronization device, and chronic inﬂammatory
disease. Written informed consent was obtained from each
patient before cardiac catheterization, and the study was
approved by the ethics committee of our institution.
Cardiac catheterization and evaluation of coronary
microvascular dysfunction. All examinations were con-
ducted in the morning on fasting patients. In a total of 14 HF
patients (16%), vasodilatory drugs, such as calcium channel
blockers, nitrates, and nicorandil, were discontinued at least 72
h before examination to eliminate the vasodilatory effects of
these drugs. A 5-F or 6-F arterial cannula was placed in theradial or femoral artery and a 6-F
venous sheath was placed in the
right femoral vein (FV). A coro-
nary sinus (CS) catheter (Good-
tec, Gifu, Japan) was advanced to
the CS from the venous sheath,
and its position was conﬁrmed by
ﬂuoroscopy with contrast media.
Blood samples were collected
simultaneously from the aortic
root (Ao), CS, and FV. Right
heart catheterization was per-
formed using a 6-F Swan-Ganz
catheter (Fukuda Denshi, Tokyo,
Japan) to measure hemodynamic
parameters. Coronary angiog-
raphy was then performed after
administration of intracoronary
isosorbide dinitrate to conﬁrm the
absence of signiﬁcant epicardial
coronary artery stenosis. After
coronary angiography, the tip
of a 0.014-inch Doppler-tipped
guidewire (FloWire, Volcano, Rancho Cordova, California)
was advanced to the proximal site of the left anterior
descending coronary artery. Adenosine triphosphate (ATP)
(150 mg/kg/min) was administrated intravenously until
achievement of maximal hyperemia to calculate ATP-induced
coronary ﬂow reserve (CFR) (19). CFR ratios <2.0 were
considered to indicate CMVD (13,19). The left ventricular
end-diastolic pressure (LVEDP) was obtained, and left ven-
triculography was performed using a 5-F pigtail catheter.
Biomarker assays and measurement of cTnT release. The
serum and plasma samples were kept frozen at 80C until
analysis. Serum cTnT levels were measured using the Elecsys
2010 Troponin T hs kit (Roche Diagnostics, Indianapolis,
Indiana). The lower limit of detection is 5 ng/l with a reported
99th percentile value in apparently healthy individuals of
13.5 ng/l. At the 99th percentile value, the coefﬁcient of
variation is 9% by Elecsys 2010 analyzer (20). Plasma B-type
natriuretic peptide (BNP) levels were measured using the
MI02 Shionogi BNP kit (Shionogi, Osaka, Japan). cTnT and
BNP release from the myocardium were calculated as the
differences betweenCS andAo levels of cTnT [DcTnT (CS
Ao)] and BNP [DBNP (CS-Ao)], respectively. Serum high-
sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6,
and tumor necrosis factor (TNF)-a, representing inﬂamma-
tory markers, were measured by the respective enzyme-linked
immunosorbent assay (ELISA) (R&D systems, Minneapolis,
Minnesota). Urinary 8-hydroxy-20-deoxyguanosine (8-OHdG)
was measured by ELISA (8-OHdG check, Japan Institute for
the Control of Aging, Shizuoka, Japan) as a marker of oxidative
stress. The level of urinary 8-OHdG was corrected to urinary
creatinine concentration.
Statistical analysis. Normally distributed datawere presented
as mean  SD, whereas data of variables with skewed
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Differences between groupswere examined by the Student t test
or the Mann-Whitney U test for unpaired data. Categorical
valueswere presented as numbers (percentage) and compared by
the chi-square test or Fisher exact test as appropriate. Receiver-
operating characteristic curves were generated to determinateTable 1
Demographic and Clinical Characteristic
Transcardiac cTnT Release
Variable
HF Grou
(n ¼ 76
Age, yrs 60  14
Male 49 (64%)
Body mass index, kg/m2 24.1  3.
NYHA functional class, I/II/III/IV 23/45/8
Hypertension 42 (55%)
Dyslipidemia 35 (46%)
Diabetes mellitus 11 (15%)
Atrial ﬁbrillation 20 (26%)
Prior HF hospitalization 15 (20%)
Hemodynamic status
Cardiac index, l/min/m2 2.39  0.
PCWP, mm Hg 11.9  4.
LVEDP, mm Hg 11.8  6.
Medications
Loop diuretics 28 (37%)
Beta-blockers 56 (74%)
ACE-I or ARB 63 (83%)
Aldosterone antagonists 30 (40%)
Digitalis 7 (9%)
Statins 22 (29%)
Laboratory and imaging ﬁndings
Ao-cTnT, ng/l 13.3 (8.9–2
FV-cTnT, ng/l 13.1 (9.3–1
Ao-BNP, pg/ml 114 (49–27
Hemoglobin, g/dl 14.0  1.
Hemoglobin A1c, % 6.0  0.
Estimated GFR, ml/min/1.73 m2 63.3  19
hs-CRP, mg/dl 0.08 (0.04–
IL-6, pg/ml (n ¼ 74) 1.37 (0.89–
TNF-alpha, pg/ml (n ¼ 68) 1.93 (1.43–
8-OHdG, ng/mg creatinine (n ¼ 47) 16.9 (11.9–
LVDd, mm 53.1  8.
LVEF, % 42.7  12
E/e0 12.4 (9.3–1
LV mass index, g/m2* 160  52
Etiology of heart failure
Dilated cardiomyopathy 36 (47%)
Hypertrophic cardiomyopathy 13 (17%)
Hypertensive cardiomyopathy 12 (16%)
Cardiac amyloidosis 4 (5%)
Valvular heart diseases 3 (4%)
Othersy 8 (11%)
Values are mean  SD, n (%), or median (interquartile range). *LV mass in
yOther etiologies included the following: tachycardia-induced cardiomyopath
opathy (n ¼ 2), LV noncompaction (n ¼ 2), and unclassiﬁed cardiomyopathy
ACE-I ¼ angiotensin-converting enzyme inhibitor; Ao-BNP ¼ B-type natriure
the aortic root; ARB ¼ angiotensin II receptor blocker; BSA ¼ body surface a
velocity to tissue Doppler early mitral annular diastolic velocity; FV ¼ femoral v
sensitivity C-reactive protein; IL ¼ interleukin; IVST ¼ interventricular septa
dimension; LVEDP ¼ left ventricular end-diastolic pressure; LVEF ¼ left ven
Association; TNF ¼ tumor necrosis factor; PCWP ¼ pulmonary capillary wedthe cutoff value for the prediction of circulating cTnT level
>13.5 ng/l. Variables with a skewed distribution were trans-
formed logarithmically beforePearson’s correlation andmultiple
regression analyses to fulﬁll the conditions required for the types
of analysis. Linear relationships betweenDcTnT (CS-Ao) levels
and key variables were ﬁrst analyzed by univariate analysiss of Participating Patients With Available
p
)
Non-HF Group
(n ¼ 28) p Value
63  14 0.48
14 (50%) 0.18
9 24.3  3.4 0.74
/0 NA
21 (75%) 0.07
21 (75%) 0.009
6 (21%) 0.39
2 (7%) 0.03
NA
64 2.93  0.87 0.001
9 9.3  3.4 0.01
8 8.2  5.6 0.02
2 (7%) 0.003
8 (29%) <0.001
12 (43%) <0.001
0 (0%) <0.001
0 (0%) 0.19
13 (46%) 0.09
1.0) 8.2 (6.3–10.4) <0.001
9.4) 6.1 (5.1–10.4) <0.001
2) 15 (5–39) <0.001
7 13.8  1.9 0.51
9 6.0  0.6 0.81
.4 69.2  13.6 0.15
0.17) 0.03 (0.02–0.06) <0.001
2.37) NA
2.61) NA
26.8) NA
7 45.3  4.8 <0.001
.1 64.7  4.9 <0.001
5.4) 11.1 (8.6–13.5) 0.19
90  19 <0.001
NA
NA
NA
NA
NA
NA
dex ¼ {1.04  [(IVST þ LVDd þ PWT)3  LVDd3]  0.8 þ 0.6}/BSA.
y (n ¼ 1), diabetic cardiomyopathy (n ¼ 1), mitochondrial cardiomy-
(n ¼ 2).
tic peptide level in the aortic root; Ao-cTnT ¼ cardiac troponin T level in
rea; cTnT ¼ cardiac troponin T; E/e0 ¼ mitral early diastolic peak ﬂow
ain; GFR¼ glomerular ﬁltration rate; HF ¼ heart failure; hs-CRP¼ high-
l thickness; LV ¼ left ventricular; LVDd ¼ left ventricular end-diastolic
tricular ejection fraction; NA ¼ not available; NYHA ¼ New York Heart
ge pressure; PWT ¼ posterior wall thickness.
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635followed by stepwise multivariate analysis. A forward stepwise
algorithm (p< 0.10 for entry, and p< 0.05 for stay) was used.
Patients who were evaluated for CFR were divided into tertiles
according to the DcTnT (CS-Ao) levels. Univariate and
multivariate logistic regression analyses were performed to
identify the independent parameters of highest tertile value.The
Hosmer-Lemeshow statistic was applied to assess model cali-
bration. A 2-tailed value of p< 0.05 was considered statistically
signiﬁcant. All statistical analyses were performed with SPSS
version 19 (SPSS, Chicago, Illinois).Results
cTnT measurement and comparison of HF and control
groups. The serum levels of cTnT in Ao (Ao-cTnT) were
detectable in 80HF patients and 28 non-HF patients (89% vs.
60%, respectively; p < 0.001). Plasma BNP levels in Ao
(Ao-BNP) was signiﬁcantly higher in HF patients with
detectable levels of serum cTnT compared with those with
undetectable levels (114 [51 to 272] pg/ml vs. 36 [11 to 92]
pg/ml; p ¼ 0.007). Age (63  13 years vs. 57  9 years;
p¼ 0.09) andLVEDP(8.2 5.6mmHgvs. 5.0 3.8mmHg;
p ¼ 0.054) tended to be higher in non-HF patients
with detectable levels of serum cTnT compared with those
with undetectable levels. The levels of serum cTnT in FV
(FV-cTnT), representing the circulating cTnT levels, corre-
lated strongly with Ao-cTnT (r ¼ 0.954, p < 0.001). The
ratio of transcardiac cTnT release to FV-cTnT level was 18.8Figure 1 Comparison of cTnT and BNP Release Between Nonischem
DcTnT (CS-Ao) and DBNP (CS-Ao) levels were signiﬁcantly higher in nonischemic HF patients
level in coronary sinus)  (BNP level in aortic root); DcTnT (CS-Ao) ¼ (cTnT level in coronar
troponin T. 14.8% in the study patients with detectable Ao-cTnT.
Receiver-operating characteristic analysis selected 2.2 ng/l as
the best cutoff value of DcTnT (CS-Ao) level for the
prediction of circulating cTnT level >13.5 ng/l, representing
the 99th percentile cutoff value of this assay, with sensitivity
and speciﬁcity of 61% and 71%, respectively, and area under
the curve of 0.66 (95% conﬁdence interval [CI]: 0.55 to 0.77;
p¼ 0.006). Similarly, 75.4 pg/ml was the best cutoff value of
Ao-BNP level for the prediction of circulating cTnT level
>13.5 ng/l with a sensitivity and speciﬁcity of 61% and 66%,
respectively, and area under the curve of 0.70 (95%CI: 0.60 to
0.80; p ¼ 0.001).
The serum cTnT levels in CS (CS-cTnT) were higher than
those of Ao-cTnT in 76 HF patients (95%) and all non-HF
patients with detectable Ao-cTnT. These results suggested
the availability of transcardiac cTnT release in these patients.
Table 1 details the baseline characteristics of the study patients
with available levels of DcTnT (CS-Ao). Among the 76 HF
patients with available DcTnT (CS-Ao), IL-6 and TNF-a
were measurable in 74 patients. IL-6 was detected in all
patients (limit of detection: 0.156 pg/ml), whereasTNF-awas
detected in 68 patients (limit of detection: 0.5 pg/ml). Urinary
8-OHdG was measurable in 47 patients.
DcTnT (CS-Ao) (2.5 [1.2 to 4.9] ng/l) and DBNP
(CS-Ao) (235 [90 to 382] pg/ml) levels of the HF patients
were signiﬁcantly higher than those of the non-HF group
(1.2 [0.5 to 1.4] ng/l; p < 0.001, and 28 [10 to 58] pg/ml;
p < 0.001, respectively) (Fig. 1).ic HF Patients and Non-HF Group
than in non-HF group. Data are median and interquartile ranges. DBNP (CS-Ao)¼ (BNP
y sinus)  (cTnT level in aortic root); BNP ¼ B-type natriuretic peptide; cTnT ¼ cardiac
Figure 2 Correlation of Log [DcTnT (CS-Ao)] With LVEDP, PCWP, Log [DBNP (CS-Ao)], and Log (FV-cTnT) in PatientsWith Nonischemic HF
LVEDP (A), PCWP (B), log [DBNP (CS-Ao)] (C), and log (FV-cTnT) (D) levels correlated positively with log [DcTnT (CS-Ao)]. FV-cTnT ¼ cTnT level in femoral vein; LVEDP ¼ left
ventricular end-diastolic pressure; PCWP ¼ pulmonary capillary wedge pressure; other abbreviations as in Figure 1.
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636Evaluation of factors associated with cTnT release. Among
the 76 HF patients with available DcTnT (CS-Ao), log
[DcTnT (CS-Ao)] levels correlated positively with pulmonaryTable 2
Results of Univariate and Multivariate Linear
Regression Analyses for Log [DcTnT (CS-Ao)]
Variable
Univariate Analysis Multivariate Analysis
b p Value b p Value
Age 0.192 0.10 Not selected
Body mass index 0.068 0.56 Not selected
Cardiac index 0.034 0.77 Not selected
PCWP 0.253 0.03 d
LVEDP 0.321 0.005 0.321 0.006
LVEF 0.126 0.28 Not selected
Log (E/e0) 0.151 0.20 Not selected
LV mass index 0.076 0.51 Not selected
Hemoglobin 0.184 0.11 Not selected
Hemoglobin A1c 0.003 0.98 Not selected
Estimated GFR 0.039 0.74 Not selected
Log (FV-cTnT) 0.494 <0.001 d
Log (Ao-BNP) 0.266 0.02 d
Log [DBNP (CS-Ao)] 0.368 0.001 d
Log (hs-CRP) 0.170 0.15 Not selected
Log (IL-6) 0.009 0.94 d
Log (TNF-alpha) 0.036 0.77 d
Log (8-OHdG) 0.004 0.98 d
“Not selected” indicates not selected by stepwise algorithm.
Abbreviations as in Table 1.capillary wedge pressure (r ¼ 0.253, p ¼ 0.03), LVEDP
(r ¼ 0.321; p ¼ 0.005), log (FV-cTnT) (r ¼ 0.494;
p < 0.001), log (Ao-BNP) (r ¼ 0.266, p ¼ 0.02), and log
[DBNP (CS-Ao)] (r ¼ 0.368, p ¼ 0.001) (Fig. 2). However,
cTnT release did not correlate with markers of inﬂammation
(hs-CRP, IL-6, and TNF-a) or oxidative stress (8-OHdG)
(Table 2). To examine the factors associated with cTnT
release, we performed stepwise multiple regression analysis.
The analysis identiﬁed LVEDP (b ¼ 0.321, p ¼ 0.006)
(Table 2) as the only independent and signiﬁcant parameter
that correlated with DcTnT (CS-Ao).
High cTnT release in HF patients with CMVD. CFR
was evaluated in 68 HF patients (76%). Among them,
DcTnT (CS-Ao) was available in 58 HF patients (85%). Log
[DcTnT (CS-Ao)] levels did not correlate with actual
CFR values (r ¼ 0.054, p ¼ 0.69). CMVD, reﬂected by
CFR <2.0, was observed in 18 HF patients with available
DcTnT (CS-Ao) (31%). Ao-cTnT, Ao-BNP, DBNP
(CS-Ao) levels, and left ventricular mass index were signif-
icantly higher and hemoglobin was lower in patients with
CMVD than in those without (Table 3), as were DcTnT
(CS-Ao) levels (4.8 [2.0 to 8.1] ng/l vs. 2.0 [1.2 to 4.6] ng/l;
p ¼ 0.04) (Fig. 3). The following variables were entered into
stepwise multiple regression analysis to identify the factors
associated with cTnT release: age, sex, the presence of
CMVD, log(hs-CRP), hemoglobin, left ventricular ejection
fraction, and left ventricular mass index. The analysis
Table 3 Clinical Characteristics of Patients With and Without CMVD
Variable
CFR <2.0
(n ¼ 18)
CFR 2.0
(n ¼ 40) p Value
Age, yrs 60  15 61  15 0.93
Male 12 (67%) 31 (78%) 0.52
Body mass index, kg/m2 24.0  4.0 24.2  3.7 0.88
NYHA functional class 2.1  0.4 1.8  0.7 0.045
Hypertension 11 (61%) 23 (58%) 0.80
Dyslipidemia 7 (39%) 19 (48%) 0.54
Diabetes mellitus 4 (22%) 6 (15%) 0.48
Cardiac index, l/min/m2 2.42  0.69 2.33  0.67 0.67
PCWP, mm Hg 11.7  3.7 12.7  5.1 0.49
LVEDP, mm Hg 12.9  7.1 11.4  5.9 0.39
CFR 1.6  0.3 3.3  0.9 <0.001
Baseline average peak ﬂow velocity, cm/s 17.0 (14.0–36.0) 15.5 (12.0–20.0) 0.06
Hyperemic average peak ﬂow velocity, cm/s 30.0 (22.5–60.5) 48.0 (37.5–62.5) 0.02
Ao-cTnT, ng/l 24.8 (14.3–50.0) 12.2 (8.3–17.6) 0.003
Ao-BNP, pg/ml 354 (149–519) 75 (33–196) <0.001
DBNP (CS-Ao), pg/ml 451 (273–569) 179 (96–304) 0.003
Hemoglobin, g/ml 13.4  1.9 14.6  1.5 0.008
Hemoglobin A1c, % 6.2  1.3 6.0  0.9 0.53
Estimated GFR, ml/min/1.73 m2 59.2  24.9 65.1  17.9 0.31
hs-CRP, mg/dl 0.10 (0.06–0.32) 0.08 (0.03–0.16) 0.09
IL-6, pg/ml 1.53 (0.99–3.53) 1.37 (0.78–2.32) 0.40
TNF-alpha, pg/ml 2.10 (1.32–2.34) 1.94 (1.42–2.61) 0.76
8-OHdG, ng/mg creatinine 28.4 (10.6–39.6) 16.1 (11.0–19.7) 0.17
LVDd, mm 54.2  10.8 53.7  8.2 0.85
LVEF, % 42.1  10.7 41.1  11.5 0.76
E/e0 14.9 (10.1–17.3) 12.6 (9.4–14.9) 0.27
LV mass index, g/m2 186  57 152  51 0.03
Etiology of heart failure
Dilated cardiomyopathy 6 (33%) 20 (50%)
Hypertrophic cardiomyopathy 3 (17%) 6 (15%)
Hypertensive cardiomyopathy 2 (11%) 9 (23%)
Cardiac amyloidosis 4 (22%) 0
Valvular heart disease 1 (6%) 1 (3%)
Others 2 (11%) 4 (10%)
Values are mean  SD, n (%), or median (interquartile range).
CMVD ¼ coronary microvascular dysfunction; CRF ¼ coronary ﬂow reserve; other abbreviations as in Table 1.
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637identiﬁed the presence of CMVD (b ¼ 0.322, p ¼ 0.02) as
an independent and signiﬁcant parameter associated with
DcTnT (CS-Ao). Multivariate logistic regression analysis was
performed to identify the independent parameters of highest
tertile value of DcTnT (CS-Ao) (cutoff value >4.2 ng/l)
among the 68 HF patients who were evaluated for CFR. The
analysis identiﬁed LVEDP (odds ratio [OR]: 1.10; 95%
CI: 1.00 to 1.21; p ¼ 0.04), and the presence of CMVD
(OR: 6.60; 95% CI: 1.75 to 24.97; p ¼ 0.005) as 2 inde-
pendent and signiﬁcant correlates with highest tertile value
of DcTnT (CS-Ao) (Table 4).
Discussion
To the best of our knowledge, this is the ﬁrst report that
measured transcardiac cTnT release from nonischemic
failing myocardium by high-sensitivity assay. The major
ﬁndings of the present study were: 1) high DcTnT (CS-Ao)levels in nonischemic HF patients compared with non-HF
patients; 2) DcTnT (CS-Ao) levels were signiﬁcantly
higher in patients with CMVD than those without; and
3) LVEDP and the presence of CMVD were signiﬁcant and
independent determinants of DcTnT (CS-Ao) levels. To-
gether, these ﬁndings indicate that increased diastolic load
and CMVD seem to be the causes of persistent and modest
cTnT release from the failing myocardium.
Serum cardiac troponin level is inﬂuenced by various
clinical factors such as renal clearance (6,15), presence of
CAD (7,11), and skeletal muscle disease (16). To exclude
the involvement of these factors, we evaluated cTnT release
directly by measuring the differences in cTnT levels between
CS and Ao in nonischemic HF patients. Tsutamoto et al.
(15) measured serum cTnT level in the Ao and CS by
conventional assay in HF patients, but detected Ao-cTnT
in only 37% of patients (the detection limit of this assay
was >10 ng/l). Moreover, CS-cTnT levels were lower than
Figure 3
Comparison of cTnT Release in the Presence and
Absence of Coronary Microvascular Dysfunction
CFR ratio <2.0 indicates existing coronary microvascular dysfunction. DcTnT
(CS-Ao) levels were signiﬁcantly higher in patients with coronary microvascular
dysfunction than in those without. Data are medians and interquartile ranges.
CFR ¼ coronary ﬂow reserve; other abbreviations as in Figure 1.
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638Ao-cTnT levels in 39% of patients tested. These data imply
that persistent and low-grade transcardiac cTnT release in
stable HF patients cannot be evaluated precisely by the
conventional assay. By comparison, we were able to detect
Ao-cTnT and positive DcTnT (CS-Ao) at high frequency
(89% and 95%, respectively) in our study group of HF
patients using the highly sensitive assay. In addition to
measuring troponin release, we recorded hemodynamics
simultaneously by right heart catheterization and evaluated
circulating cTnT levels and coronary microvascular function
using an intracoronary Doppler guidewire, enabling us to
evaluate precisely the factors associated with cTnT release
from the failing myocardium.
Elevated cardiac troponin levels correlate with elevated
BNP levels and impaired hemodynamics in patients with
HF (11,21). Kusumoto et al. (22) measured circulating
cTnT levels by highly sensitive assay in HF patients and
described a positive correlation between circulating BNP
and cTnT levels. However, they did not eliminate the effect
of confounding factors, such as renal function and myocar-
dial ischemia. By comparison, we examined transcardiac
cTnT release to identify the mechanism of its release after
excluding these confounding factors in nonischemic HF
patients. Therefore, our methodology and purpose are novel
and deﬁnitely different from the aforementioned study. In
the present study, univariate analysis conﬁrmed that cTnTrelease correlated positively with BNP release. These results
suggest that cTnT release is associated with wall stress in the
failing myocardium because BNP is released from the heart
in response to volume expansion and pressure overload as-
sociated with wall stress (23). Moreover, previous studies
reported that circulating cTnT levels correlated positively
with N-terminal pro-BNP levels even in non-HF patients
(8). In our study, BNP release also correlated positively with
cTnT release in non-HF patients similar to HF patients
(r ¼ 0.546, p ¼ 0.01). Thus, we speculate that transcardiac
cTnT release in non-HF patients could be potentially a
signal of subtle increase in wall stress though inadequate to
provoke HF symptoms.
How does wall stress in the absence of myocardial necrosis
change cardiac troponin release? Although the exact mech-
anism is unknown at this stage, several mechanisms have
been postulated. Hessel et al. (14) reported that intact
cardiac troponin I was released from viable cardiomyocytes
on stimulation of the stretch-responsive integrins without an
increase in lactate production, inferring that release can
occur without ischemia or necrosis. Furthermore, Clarke
et al. (24) reported that mechanical stimuli might produce
transient disruption of the myocardial plasma membrane,
suggesting increased membrane permeability as a potential
mechanism. These reports and our present ﬁndings indicate
that stretch and mechanical stress of cardiac myocytes might
lead to leakage of the intact troponin from the cytosolic
pool with a transient loss of cell membrane integrity and
increased membrane permeability. However, it remains
unclear whether the threshold level and amount of released
cardiac troponin are different between normal heart and
failing heart under these circumstances, and further studies
are needed to clarify this point.
Activation of inﬂammatory cytokines and oxidative stress
are presumed to increase serum cTnT level in HF (11);
however, our study showed these factors to be unrelated to
cTnT release. This could be related to the patient selection
criteria applied in the present study; the majority of our
patients had only mild symptoms (89% were New York Heart
Association functional class I or II) and were under optimal
medication. Because inﬂammatory cytokines and oxidative
stress increase with the progression of HF (25,26), the asso-
ciation between cTnT release and these factors might be ap-
plicable only to patients with advanced HF. On the other
hand, statins and carvedilol are reported to reduce inﬂamma-
tion and oxidative stress (27,28). However, in this study, there
was no difference in cTnT release and inﬂammatory cytokine
levels between subjects treated with or without statins and
beta-blockers (data not shown). Nevertheless; we cannot rule
out possible interference of these medications with our results.
CMVD is an established feature of nonischemic cardio-
myopathies, which can also exacerbate HF and worsen
prognosis (29,30). Several mechanisms have been proposed
to explain the development of CMVD in HF, such as
increased extramural compression due to elevated LVEDP,
endothelial dysfunction, vascular remodeling, and decreased
Table 4
Results of Univariate and Multivariate Logistic Regression Analyses for Parameters
That Correlated with Highest Tertile Value of DcTnT (CS-Ao)
Variables
Univariate Analysis Multivariate Analysis
p Value OR (95% CI) p Value OR (95% CI)
Age, per yr 0.59 0.99 (0.96–1.02) Not selected
Male, yes 0.74 0.83 (0.27–2.51) Not selected
Body mass index, per kg/m2 0.88 1.01 (0.89–1.14) Not selected
NYHA functional class III, yes 0.47 2.11 (0.41–6.99) Not selected
Hypertension, yes 0.35 1.68 (0.58–4.63) Not selected
Dyslipidemia, yes 0.93 1.05 (0.38–2.87) Not selected
Diabetes mellitus, yes 0.28 0.46 (0.12–1.86) Not selected
Cardiac index, per l/min/m2 0.89 0.95 (0.43–2.07) Not selected
PCWP, per mm Hg 0.14 1.09 (0.97–1.22) d
LVEDP, per mm Hg 0.01 1.11 (1.02–1.21) 0.040 1.10 (1.00–1.21)
Presence of CMVD, yes 0.006 4.98 (1.58–15.69) 0.005 6.60 (1.75–24.97)
DBNP (CS-Ao), per pg/ml 0.007 1.00 (1.00–1.01) d
Hemoglobin, per g/dl 0.79 1.04 (0.78–1.39) Not selected
Estimated GFR, per ml/min/1.73 m2 0.92 1.00 (0.98–1.03) Not selected
Hemoglobin A1c, per % 0.76 0.93 (0.58–1.49) Not selected
hs-CRP, per mg/dl 0.87 0.83 (0.10–7.23) Not selected
LVEF, per % 0.37 1.02 (0.98–1.07) Not selected
E/e0 , per 1.00 0.77 1.02 (0.92–1.12) Not selected
LV mass index, per g/m2 0.42 1.00 (0.99–1.01) Not selected
“Not selected” indicates not selected by stepwise algorithm.
CI ¼ conﬁdence interval; OR ¼ odds ratio; other abbreviations as in Tables 1 and 3.
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639myocardial capillary density (13,31). Indeed, CMVD im-
pairs myocardial perfusion and induces regional metabolic
changes as in recurrent or persistent myocardial ischemia
(32,33). In the present study, we demonstrated that elevated
LVEDP and CMVD were associated with cTnT release.
Thus, it is possible that the elevated LVEDP is linked to
CMVD through the resultant compression of myocardial
capillaries, with subsequent decrease in their lumina, leading
to increased myocardial contractility, which in turn can cause
functional myocardial ischemia and cTnT release.
Are our ﬁndings important clinically? Because increased
LVEDP and CMVD are modiﬁable targets that can reduce
cTnT release, interventions aimed at improving these
factors should prevent exacerbation of HF and worsening
prognosis. In the present study, we did not evaluate cTnT
release in decompensated or acute HF; however, we assume
that left ventricular diastolic load and CMVD potentially
enhance cTnT release in decompensated situation. High
circulating cTnT levels result in impaired hemodynamics,
and serial measurements may be useful for the assessment of
left ventricular pressure overload, functional myocardial
ischemia, and effects of therapeutic intervention.
Study limitations. An important point to consider with the
study ﬁndings is that HF etiology could be heterogeneous
and the mechanisms of cTnT release might differ among
cardiomyopathies. In addition, this study investigated only
a relatively small number of patients in a single center and was
limited to patients with nonischemic and well-compensated
HF. Further large studies including decompensated HF
patients are warranted to conﬁrm our observations. Several
studies reported that vasodilators affect coronarymicrocirculation (34,35). Thus, we discontinued these drugs
to eliminate any exogenous effect on the coronary microcir-
culation. On the other hand, it was reported that discontin-
uation of these drugs could affect the hemodynamics and alter
endothelial function (36). Although the number of our
patients who required discontinuation of their medications
was relatively small (16%) and such patients had enough drug
holidays (>72 h), we cannot exclude a possible rebound
phenomenon and its effect on our results. Finally, we evalu-
ated CMVD by CFR of only the left anterior descending
coronary artery area; however, cardiomyopathy is character-
ized by global myocardial dysfunction, and we assumed
that CMVD would be homogenously distributed throughout
the myocardium.
Conclusions
The present study demonstrated an increased release of
cTnT from the myocardium of nonischemic HF patients
compared with non-HF patients, and such an increase
correlated with increased left ventricular diastolic load and
CMVD. These factors could contribute to persistent and
modest cTnT elevation in nonischemic HF patients, exac-
erbate HF, and worsen prognosis. Thus, therapeutic or
preventive interventions aimed at improving these factors to
reduce cTnT release in patients with HF should be applied
to escape the vicious cycle of worsening HF syndrome.Acknowledgments
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